{"id":5282,"date":"2025-03-13T14:09:31","date_gmt":"2025-03-13T08:39:31","guid":{"rendered":"https:\/\/trending.niftytrader.in\/?p=5282"},"modified":"2025-05-26T13:37:55","modified_gmt":"2025-05-26T08:07:55","slug":"brokerages-raise-concerns-over-zydus-lifes-costly-amplitude-surgical-acquisition","status":"publish","type":"post","link":"https:\/\/www.niftytrader.in\/markets\/brokerages-raise-concerns-over-zydus-lifes-costly-amplitude-surgical-acquisition\/","title":{"rendered":"Brokerages Raise Concerns Over Zydus Life\u2019s Costly Amplitude Surgical Acquisition"},"content":{"rendered":"<p data-start=\"93\" data-end=\"207\"><em data-start=\"93\" data-end=\"205\">Analysts caution that the high acquisition price and weak synergies could lead to EPS dilution for Zydus Life.<\/em><\/p>\n<h4 data-start=\"209\" data-end=\"251\">High-Cost Deal Raises Red Flags<\/h4>\n<p data-start=\"252\" data-end=\"518\">Zydus Lifesciences&#8217; decision to acquire an 85.6% stake in France-based medtech firm Amplitude Surgical for \u20ac300 million (\u20b92,700 crore) has received a lukewarm response from analysts, who believe the deal is expensive and lacks meaningful synergies.<\/p>\n<ul data-start=\"520\" data-end=\"933\">\n<li data-start=\"520\" data-end=\"632\">The acquisition is being executed at a massive 81% premium to Amplitude Surgical\u2019s current market price.<\/li>\n<li data-start=\"633\" data-end=\"826\">Brokerages Nuvama Institutional Equities, Nomura, and UBS have raised concerns over the deal\u2019s limited strategic fit with Zydus&#8217; core pharmaceutical and wellness businesses.<\/li>\n<li data-start=\"827\" data-end=\"933\">EPS dilution of 1\u20133% is expected in FY26\u201327, as per estimates from both Nomura and Nuvama.<\/li>\n<\/ul>\n<h4 data-start=\"935\" data-end=\"981\">Brokerages&#8217; Take on the Acquisition<\/h4>\n<ol data-start=\"982\" data-end=\"1866\">\n<li data-start=\"982\" data-end=\"1351\">\n<p data-start=\"985\" data-end=\"998\">Nomura:<\/p>\n<ul data-start=\"1002\" data-end=\"1351\">\n<li data-start=\"1002\" data-end=\"1132\">Warns that MedTech operates differently from pharmaceuticals, requiring distinct R&amp;D and product development capabilities.<\/li>\n<li data-start=\"1136\" data-end=\"1235\">Sees limited synergies between pharma, wellness, and MedTech, apart from market access.<\/li>\n<li data-start=\"1239\" data-end=\"1351\">Estimates EPS dilution of 1.5\u20133% in FY27 but retains a \u2018Buy\u2019 call with a price target of \u20b91,140.<\/li>\n<\/ul>\n<\/li>\n<li data-start=\"1353\" data-end=\"1656\">\n<p data-start=\"1356\" data-end=\"1392\">Nuvama Institutional Equities:<\/p>\n<ul data-start=\"1396\" data-end=\"1656\">\n<li data-start=\"1396\" data-end=\"1558\">Notes that Amplitude Surgical lacks the scale to offset rising competition in Lenalidomide (Revlimid), one of Zydus\u2019 key drugs facing revenue decline.<\/li>\n<li data-start=\"1562\" data-end=\"1656\">Cuts Zydus Life\u2019s price target by 16% to \u20b9840 while maintaining a \u2018Reduce\u2019 rating.<\/li>\n<\/ul>\n<\/li>\n<li data-start=\"1658\" data-end=\"1866\">\n<p data-start=\"1661\" data-end=\"1671\">UBS:<\/p>\n<ul data-start=\"1675\" data-end=\"1866\">\n<li data-start=\"1675\" data-end=\"1743\">Reaffirms its \u2018Sell\u2019 rating with a price target of \u20b9850.<\/li>\n<li data-start=\"1747\" data-end=\"1866\">Calls the acquisition too expensive and warns of cash reserve depletion, impacting near-term profitability.<\/li>\n<\/ul>\n<\/li>\n<\/ol>\n<h4 data-start=\"1868\" data-end=\"1915\">Strategic Risks and Financial Impact<\/h4>\n<ul data-start=\"1916\" data-end=\"2344\">\n<li data-start=\"1916\" data-end=\"2159\">Long Amortization Period: Assuming 50-100% of the acquisition cost exceeding book value is classified as an intangible asset and amortized over 15\u201320 years, Nomura expects limited immediate financial benefits for Zydus.<\/li>\n<li data-start=\"2160\" data-end=\"2344\">Execution Challenges: MedTech is dominated by established global players with strong customer loyalty, making it difficult for new entrants like Zydus to gain traction.<\/li>\n<\/ul>\n<h4 data-start=\"2346\" data-end=\"2386\">Zydus&#8217; Rationale for the Deal<\/h4>\n<p data-start=\"2387\" data-end=\"2609\">The acquisition is seen as a long-term diversification strategy to compensate for declining revenue from cancer drug Revlimid, but analysts believe the move comes at a significant cost with uncertain returns.<\/p>\n<p data-start=\"2611\" data-end=\"2789\" data-is-last-node=\"\" data-is-only-node=\"\">While the company is betting on MedTech\u2019s strong growth potential, brokerages remain cautious due to execution risks, limited synergies, and the high acquisition premium.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Analysts caution that the high acquisition price and weak synergies could lead to EPS dilution for Zydus Life. High-Cost Deal Raises Red Flags Zydus Lifesciences&#8217; decision to acquire an 85.6% stake in France-based medtech firm Amplitude Surgical for \u20ac300 million (\u20b92,700 crore) has received a lukewarm response from analysts, who believe the deal is expensive [&hellip;]<\/p>\n","protected":false},"author":4,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1362,615],"tags":[],"ppma_author":[1331],"class_list":{"0":"post-5282","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-finance-and-economy-news","8":"category-stock-market-news"}," _eael_post_view_count":0,"authors":[{"term_id":1331,"user_id":4,"is_guest":0,"slug":"sourabh","display_name":"Sourabh Sharma","avatar_url":{"url":"https:\/\/trending.niftytrader.in\/wp-content\/uploads\/2025\/11\/Sourabh-Sharma.png","url2x":"https:\/\/trending.niftytrader.in\/wp-content\/uploads\/2025\/11\/Sourabh-Sharma.png"},"0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":""}],"_links":{"self":[{"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/posts\/5282","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/comments?post=5282"}],"version-history":[{"count":1,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/posts\/5282\/revisions"}],"predecessor-version":[{"id":5284,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/posts\/5282\/revisions\/5284"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/media\/5283"}],"wp:attachment":[{"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/media?parent=5282"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/categories?post=5282"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/tags?post=5282"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/ppma_author?post=5282"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}